{
  "drug_name": "Oxcarbazepine",
  "url": "https://wikem.org/wiki/Oxcarbazepine",
  "scraped_at": "2026-01-10T07:59:02.621146",
  "sections": {
    "Administration": {
      "text": "Type:\nAntiepileptics\nDosage Forms: 150,300,600mg; 300mg/5 mL\nRoutes of Administration: PO\nCommon Trade Names: Trileptal",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Antiepileptics",
          "url": "https://wikem.org/wiki/Antiepileptics"
        }
      ]
    },
    "Adult_Dosing": {
      "text": "",
      "subsections": {
        "Partial_seizures": {
          "text": "adjunct treatment: Dose: 600mg PO bid; Start: 300mg PO bid, increase by up to 600mg/day qwk; Max: 2400mg/day;\nconversion to monotherapy: Dose: 1200mg PO bid; Start: 300mg PO bid, increase by up to 600mg/day qwk; Max: 2400mg/day; discontinue concomitant anticonvulsants over 3-6wk; taper dose gradually to discontinue\ninitial monotherapy: Dose: 600mg PO bid; Start: 300mg PO bid, increase by 300mg/day q3 days; Max: 2400mg/day",
          "tables": []
        },
        "Trigeminal_neuralgia": {
          "text": "450-1200mg PO bid\nStart: 300mg PO bid, may increase by 600mg/day qwk",
          "tables": []
        },
        "Bipolar_disorder": {
          "text": "600-1200mg PO bid\nStart: 300mg PO bid, increase by 300mg/day q3 days or by 600mg/day qwk",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Partial_seizures": {
      "text": "adjunct treatment: Dose: 600mg PO bid; Start: 300mg PO bid, increase by up to 600mg/day qwk; Max: 2400mg/day;\nconversion to monotherapy: Dose: 1200mg PO bid; Start: 300mg PO bid, increase by up to 600mg/day qwk; Max: 2400mg/day; discontinue concomitant anticonvulsants over 3-6wk; taper dose gradually to discontinue\ninitial monotherapy: Dose: 600mg PO bid; Start: 300mg PO bid, increase by 300mg/day q3 days; Max: 2400mg/day",
      "subsections": {
        "Trigeminal_neuralgia": {
          "text": "450-1200mg PO bid\nStart: 300mg PO bid, may increase by 600mg/day qwk",
          "tables": []
        },
        "Bipolar_disorder": {
          "text": "600-1200mg PO bid\nStart: 300mg PO bid, increase by 300mg/day q3 days or by 600mg/day qwk",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Trigeminal_neuralgia": {
      "text": "450-1200mg PO bid\nStart: 300mg PO bid, may increase by 600mg/day qwk",
      "subsections": {
        "Bipolar_disorder": {
          "text": "600-1200mg PO bid\nStart: 300mg PO bid, increase by 300mg/day q3 days or by 600mg/day qwk",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Bipolar_disorder": {
      "text": "600-1200mg PO bid\nStart: 300mg PO bid, increase by 300mg/day q3 days or by 600mg/day qwk",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pediatric_Dosing": {
      "text": "",
      "subsections": {
        "adjunct_therapy": {
          "text": "2-3 yo\nDose: 60mg/kg/day PO divided bid; Start: 8-10mg/kg/day PO divided BID up to 600mg/day, increase dose over 2-4wk; Max: 60mg/kg/day\nmay start 16-20mg/kg/day PO divided BID in patients <20 kg\n4-16 yo, 20-29 kg\nDose: 600mg PO bid; Start: 8-10mg/kg/day PO divided BID up to 600mg/day, increase to target dose over 2wk\n4-16 yo, >39 kg\nDose: 900mg PO bid; Start: 8-10mg/kg/day PO divided BID up to 600mg/day, increase to target dose over 2wk",
          "tables": []
        },
        "monotherapy": {
          "text": "4-16 yo, 20-24 kg\nDose: 300-450mg PO bid; Start: 8-10mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10mg/kg/day qwk if conversion to monotherapy\nDiscontinue concomitant anticonvulsants over 3-6wk\n4-16 yo, 25-34 kg\nDose: 450-600mg PO bid; Start: 8-10mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10mg/kg/day qwk if conversion to monotherapy\nDiscontinue concomitant anticonvulsants over 3-6wk\n4-16 yo, 35-44 kg\nDose: 450-750mg PO bid; Start: 8-10mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10mg/kg/day qwk if conversion to monotherapy\nDiscontinue concomitant anticonvulsants over 3-6wk\n4-16 yo, 45-49 kg\nDose: 600-750mg PO bid; Start: 8-10mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10mg/kg/day qwk if conversion to monotherapy\nDiscontinue concomitant anticonvulsants over 3-6wk\n4-16 yo, 50-59 kg\nDose: 600-900mg PO bid; Start: 8-10mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10mg/kg/day qwk if conversion to monotherapy\nDiscontinue concomitant anticonvulsants over 3-6wk\n4-16 yo, 60-69 kg\nDose: 600-1050mg PO bid; Start: 8-10mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10mg/kg/day qwk if conversion to monotherapy\nDiscontinue concomitant anticonvulsants over 3-6wk\n4-16 yo, >70 kg\nDose: 750-1050mg PO bid; Start: 8-10mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10mg/kg/day qwk if conversion to monotherapy\nDiscontinue concomitant anticonvulsants over 3-6wk",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Partial_seizures_2": {
      "text": "",
      "subsections": {
        "adjunct_therapy": {
          "text": "2-3 yo\nDose: 60mg/kg/day PO divided bid; Start: 8-10mg/kg/day PO divided BID up to 600mg/day, increase dose over 2-4wk; Max: 60mg/kg/day\nmay start 16-20mg/kg/day PO divided BID in patients <20 kg\n4-16 yo, 20-29 kg\nDose: 600mg PO bid; Start: 8-10mg/kg/day PO divided BID up to 600mg/day, increase to target dose over 2wk\n4-16 yo, >39 kg\nDose: 900mg PO bid; Start: 8-10mg/kg/day PO divided BID up to 600mg/day, increase to target dose over 2wk",
          "tables": []
        },
        "monotherapy": {
          "text": "4-16 yo, 20-24 kg\nDose: 300-450mg PO bid; Start: 8-10mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10mg/kg/day qwk if conversion to monotherapy\nDiscontinue concomitant anticonvulsants over 3-6wk\n4-16 yo, 25-34 kg\nDose: 450-600mg PO bid; Start: 8-10mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10mg/kg/day qwk if conversion to monotherapy\nDiscontinue concomitant anticonvulsants over 3-6wk\n4-16 yo, 35-44 kg\nDose: 450-750mg PO bid; Start: 8-10mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10mg/kg/day qwk if conversion to monotherapy\nDiscontinue concomitant anticonvulsants over 3-6wk\n4-16 yo, 45-49 kg\nDose: 600-750mg PO bid; Start: 8-10mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10mg/kg/day qwk if conversion to monotherapy\nDiscontinue concomitant anticonvulsants over 3-6wk\n4-16 yo, 50-59 kg\nDose: 600-900mg PO bid; Start: 8-10mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10mg/kg/day qwk if conversion to monotherapy\nDiscontinue concomitant anticonvulsants over 3-6wk\n4-16 yo, 60-69 kg\nDose: 600-1050mg PO bid; Start: 8-10mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10mg/kg/day qwk if conversion to monotherapy\nDiscontinue concomitant anticonvulsants over 3-6wk\n4-16 yo, >70 kg\nDose: 750-1050mg PO bid; Start: 8-10mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10mg/kg/day qwk if conversion to monotherapy\nDiscontinue concomitant anticonvulsants over 3-6wk",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Special_Populations": {
      "text": "Pregnancy Rating\n: C\nLactation risk\n: safety unknown",
      "subsections": {
        "Renal_Dosing": {
          "text": "Adult: CrCl <30: start 150mg bid; HD/PD: no supplement; Info: titrate dose slowly until response\nPediatric: CrCl <30: decrease start dose 50%, max start dose 300mg/24h; HD/PD: no supplement; Info: titrate dose slowly until response",
          "tables": []
        },
        "Hepatic_Dosing": {
          "text": "Adult: mild-mod impairment: no adjustment; severe impairment: not defined\nPediatric: mild-mod impairment: no adjustment; severe impairment: not defined",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "Pregnancy Rating",
          "url": "https://wikem.org/wiki/Drug_Ratings_in_Pregnancy"
        },
        {
          "text": "Lactation risk",
          "url": "https://wikem.org/wiki/Lactation_risk_categories"
        }
      ]
    },
    "Renal_Dosing": {
      "text": "Adult: CrCl <30: start 150mg bid; HD/PD: no supplement; Info: titrate dose slowly until response\nPediatric: CrCl <30: decrease start dose 50%, max start dose 300mg/24h; HD/PD: no supplement; Info: titrate dose slowly until response",
      "subsections": {
        "Hepatic_Dosing": {
          "text": "Adult: mild-mod impairment: no adjustment; severe impairment: not defined\nPediatric: mild-mod impairment: no adjustment; severe impairment: not defined",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Hepatic_Dosing": {
      "text": "Adult: mild-mod impairment: no adjustment; severe impairment: not defined\nPediatric: mild-mod impairment: no adjustment; severe impairment: not defined",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Contraindications": {
      "text": "Allergy to class/drug\nHLA-B*1502 allele (treatment-naive patients)\navoid abrupt withdrawal\ncaution if hypersens. to carbamazepine\ncaution in elderly patients\ncaution in pregnancy\ncaution if hyponatremia\ncaution if renal impairment\ncaution if depression or history",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adverse_Reactions": {
      "text": "",
      "subsections": {
        "Serious": {
          "text": "hyponatremia\nanaphylaxis\nangioedema\ndrug reaction with eosinophilia and systemic sx\nStevens-Johnson syndrome\ntoxic epidermal necrolysis\nerythema multiforme\nacute generalized exanthematous pustulosis\nsuicidality\nleukopenia\nthrombocytopenia\npancytopenia\nagranulocytosis\naplastic anemia\npancreatitis\nwithdrawal seizures if abrupt discontinuation\nwithdrawal symptoms if abrupt discontinuation",
          "tables": []
        },
        "Common": {
          "text": "dizziness\nheadache\nnausea/vomiting\nsomnolence\ndiplopia\nbalance disorder\nfatigue/asthenia\ntremor\nhyponatremia\nvisual disturbance\nnystagmus\nataxia\nabnormal gait\nabdominal pain\ndyspepsia\ngastritis\ndiarrhea\nconstipation\ncognitive dysfunction\nimpaired concentration\nconfusion\nURI sx\nrash\nnervousness\ninsomnia\nacne\nphotosensitivity",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Serious": {
      "text": "hyponatremia\nanaphylaxis\nangioedema\ndrug reaction with eosinophilia and systemic sx\nStevens-Johnson syndrome\ntoxic epidermal necrolysis\nerythema multiforme\nacute generalized exanthematous pustulosis\nsuicidality\nleukopenia\nthrombocytopenia\npancytopenia\nagranulocytosis\naplastic anemia\npancreatitis\nwithdrawal seizures if abrupt discontinuation\nwithdrawal symptoms if abrupt discontinuation",
      "subsections": {
        "Common": {
          "text": "dizziness\nheadache\nnausea/vomiting\nsomnolence\ndiplopia\nbalance disorder\nfatigue/asthenia\ntremor\nhyponatremia\nvisual disturbance\nnystagmus\nataxia\nabnormal gait\nabdominal pain\ndyspepsia\ngastritis\ndiarrhea\nconstipation\ncognitive dysfunction\nimpaired concentration\nconfusion\nURI sx\nrash\nnervousness\ninsomnia\nacne\nphotosensitivity",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Common": {
      "text": "dizziness\nheadache\nnausea/vomiting\nsomnolence\ndiplopia\nbalance disorder\nfatigue/asthenia\ntremor\nhyponatremia\nvisual disturbance\nnystagmus\nataxia\nabnormal gait\nabdominal pain\ndyspepsia\ngastritis\ndiarrhea\nconstipation\ncognitive dysfunction\nimpaired concentration\nconfusion\nURI sx\nrash\nnervousness\ninsomnia\nacne\nphotosensitivity",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pharmacology": {
      "text": "Half-life: 2h (parent drug), 7-11h (parent drug, ER form), 9h (metabolite)\nMetabolism: liver; CYP450: 2C19 inhibitor; 3A4/5 inducer; Info: active metabolite\nExcretion: urine 95% (<1% unchanged), feces <4%",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Mechanism_of_Action": {
      "text": "blocks voltage-sensitive Na channels, stabilizes neural membranes, inhibits repetitive firing, and decreases synaptic impulse propagation",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "See_Also": {
      "text": "Seizures\nAnticonvulsants",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Seizures",
          "url": "https://wikem.org/wiki/Seizures"
        },
        {
          "text": "Anticonvulsants",
          "url": "https://wikem.org/wiki/Anticonvulsants"
        }
      ]
    },
    "References": {
      "text": "epocrates",
      "subsections": {},
      "tables": [],
      "links": []
    }
  }
}